欣诺基通过减轻ER压力来预防糖尿病急性损伤
Tahib Habshi1, Hrushikesh Kulkarni1, Neha Dagar1
1Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani, Rajasthan, India.
Cell biology international
|February 27, 2025
概括
欣诺基是一种天然化合物,通过减少内质网膜 (ER) 应激和炎症,显示出有望保护糖尿病急性损伤 (AKI). 这项研究证明了它在细胞培养和糖尿病大鼠中的保护作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病状况显著增加急性损伤 (AKI) 的风险,往往进展为慢性病 (CKD).
- 缺血-再输液损伤 (IRI) 通过内质网膜 (ER) 应激和炎症加剧糖尿病AKI,有效治疗方法有限.
- 迫切需要新的治疗策略来缓解糖尿病AKI的进展.
研究的目的:
- 调查自然醇化合物欣诺基对糖尿病AKI的脏保护潜力.
- 在糖尿病AKI模型中评估hinokitiol降低ER压力,炎症和亡的能力.
- 阐明欣诺基治疗作用的基础分子机制.
主要方法:
- 在体外:NRK-52E细胞在高葡萄糖条件下经历了低氧/反损伤 (HRI) 随着或没有hinokitiol预处理.
- 在体内:患有链毒素 (STZ) 诱导糖尿病的Wistar大鼠接受了双边IRI,随后接受了hinoquitiol治疗.
- 评估了ER压力标志物 (BiP,PERK,eIF2α),炎症蛋白,细胞亡,血BUN,肌素,尿道KIM-1和管道损伤.
主要成果:
- 在实验室中,欣诺基的预处理显著降低了ER压力标志物和炎症蛋白.
- 欣诺基在NRK-52E细胞中降低了亡,并在糖尿病AKI大鼠中减弱了BUN,肌素和KIM-1水平的升高.
- 在体内,欣诺基降低了管管损伤和ER应激蛋白表达,调节了PERK/CHOP/NF-κB轴.
结论:
- 欣诺基在体外和体外模型中都显示出对糖尿病AKI的显著保护作用.
- 该化合物通过减轻ER压力,炎症和亡来缓解糖尿病AKI,可能通过PERK/CHOP/NF-κB途径.
- 欣诺基代表了治疗糖尿病损伤的有希望的候选药物.
相关概念视频
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
01:22Heart Failure Drugs: Diuretics
324
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
324
01:25Antihypertensive Drugs: Direct Renin Inhibitors
468
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468